Bristol-Myers Squibb completes acquisition of Cardioxyl Pharmaceuticals, Inc.
Wednesday, December 09, 2015
Bristol-Myers Squibb Company announced that it has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.
The transaction includes full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in Phase 2 clinical development as an intravenous treatment for acute decompensated heart failure (ADHF).
news.bms.com
